Pharma News

Agenus Inc. announced that the FDA has granted Fast Track Designation to the experimental combination of botensilimab (AGEN1181) and balstilimab (AGEN2034).  ...

After circling around the crop of biotechs ripe for a takeover, Big Pharma companies have finally decided to strike.

GSK has agreed to acquire late-stage biopharma BELLUS Health, for a total of £1.6 billion. A novel P2X3 antagonist is set to advance GSK’s respiratory pipeline as part of its planned acquisition...

Supplementation or dietary intake of omega-3 fatty acid may reduce the risk for cognitive decline.

License and development agreement with Janssen leverages Pipeline’s expertise in precision neuroregeneration and Janssen’s development experience across nervous system disorders ...

Prometheus’s PRA023 is being developed to treat Crohn’s disease, ulcerative colitis and other autoimmune conditions.

The MCG solution helps detect myocardial ischemia in patients suspected of having coronary microvascular disease.

The FDA issued a complete response letter to Eli Lilly indicating it cannot approve the company’s biologic license application seeking approval for mirikizumab as a treatment for ulcerative colit...

The FDA has granted Fast Track designation to Regenxbio’s RGX-202 candidate as a potential one-time gene therapy treatment for Duchenne muscular dystrophy.

The FDA has accepted for review a supplemental biologics license application for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with...

When former U.S. Food and Drug Administration (FDA) commissioner Dr. Jane Henney approved the abortion pill mifepristone in 2000, she knew the decision was an important one for women’s health. It...

The next-generation of anti- amyloid beta therapeutics could be advanced by Biogen exercising the option to develop Denali’s antibody programme.